Comparison of the Postoperative Analgesic Efficacy of SAP and SPSIP Blocks in Patients Undergoing Mammoplasty

Abant Izzet Baysal University

Status: Not yet enrolling

Conditions: Postoperative Pain; Postsurgical Pain; Breast Pain

Treatments: Procedure: Serratus Posterior Superior Intercostal Plane Block; Procedure: Serratus Anterior Plane Block

Study type: Interventional

Funder types: Other

Identifiers

NCT07302399

AIBU-TF-AR-II-005 (Registry Identifier)

Details and patient eligibility

About

The aim is to compare the postoperative analgesic efficacy of serratus anterior plane block (SAPB) and serratus posterior superior intercostal plane block (SPSIPB) in patients undergoing mammoplasty surgery. To this end, a double-blind, randomized, controlled study has been designed. Female patients aged 18-65 years who will undergo mammoplasty surgery will be included in the study. Postoperative pain levels, opioid consumption, duration of analgesic requirement, and patient satisfaction will be evaluated in patients who receive fascial blocks for analgesic purposes.

Full description

Pain management after breast surgery plays an important role in the patients' recovery process. Therefore, investigating effective and safe analgesic methods is important for improving patient comfort in the postoperative period. The serratus anterior plane block (SAPB) is a regional anesthesia technique commonly used for pain control after breast surgery. SAPB has been shown to be effective in reducing postoperative pain and decreasing opioid consumption. In addition, SAPB is easy to perform and has a low risk of complications. The serratus posterior superior intercostal plane block (SPSIPB) is a new technique developed to provide analgesia in thoracic surgeries. SPSIPB has been reported to be effective in reducing postoperative pain and decreasing analgesic consumption. However, data on the efficacy of SPSIPB in breast surgery are limited. This study aims to compare the postoperative analgesic efficacy of SAPB and SPSIPB in patients undergoing mammoplasty. For this purpose, a double-blind, randomized, controlled trial has been designed.

Enrollment: 60 estimated patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients aged 18-85 years
• Patients undergoing elective mammoplasty
• ASA physical status I-II

Exclusion criteria

• Patients who refuse to participate
• Mentally disabled patients
• Presence of infection at the injection site
• Patients with coagulopathy
• History of allergy or toxicity to local anesthetics
• Patients with uncontrolled hypertension
• Patients with uncontrolled diabetes mellitus
• Patients with hepatic or renal failure
• Pregnant, breastfeeding women

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

SAPB Group

Active Comparator group

Description:

Serratus Anterior Plane Group Drug: 0,25% Bupivacaine 0,5ml/kg (max.20ml) will be used for blocks for each side.

Treatment:

Procedure: Serratus Anterior Plane Block

SPSIPB Group

Experimental group

Description:

Serratus Posterior Superior Intercostal Plane Block Group Drug: 0,25% Bupivacaine 0,5ml/kg (max.20ml) will be used for blocks for each side.

Treatment:

Procedure: Serratus Posterior Superior Intercostal Plane Block